Company intelligence / Profile preview

FullHope Biomedical Co., Ltd.

New Taipei City, Taiwanfhb.com.tw ↗

Ownership: Private
Development stage: Other

Overview

The company has multiple programs in development, with their lead candidate FHCT001 for solid tumors in Phase 1, FHCT003 for solid tumors with IND approval, and FHCT002 for autoimmune diseases in preclinical stage. They also have a Dendritic Killer Cell (DKC) therapy for Hepatocellular Carcinoma in pending status.

Therapeutic areas: OncologyImmunology
Modalities: Immune cell therapyCAR-NKCell-based immunotherapies
Industry: Biotech

Drug pipeline

3 assets

FHCT001

2 more assets in the full pipeline.

Request access →

Partnerships

Major medical centersInternational partnerships in development

Beyond the preview

Go deeper on FullHope Biomedical Co., Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FullHope Biomedical Co., Ltd..

Explore the full profile